Join us for an interview with Prof Kostas Stamatopoulos, as he shares his personal journey as both a medical doctor and a researcher in hematology and understand how these two activities have always been profoundly linked in his drive to deliver impactful solutions for patients - even though years may pass between a discovery and a change for patients in clinical practice. Prof Stamatopoulos describes here his work into stereotypy of B-cell receptor (BCR) immunoglobulin and how this phenomenon e...
Feb 28, 2025•24 min•Ep 134•Transcript available on Metacast This podcast episode is derived from the MDS Algorithm on EHA Campus . Check out the MDS Algorithm, which is an expert based tool for healthcare providers, ensuring a structured and evidence-based approach to managing myelodysplastic syndromes. In this episode, our host Prof Kirsten Grønbæk from University of Copenhagen, discusses the management of high-risk MDS with Prof Katharina Götze from Technical University of Munich and Prof Valeria Santini from University of Florence. The experts delve i...
Feb 14, 2025•35 min•Ep 133•Transcript available on Metacast In this episode on recent insights about metabolism of the hematopoietic stem cells (HSCs), Dr Krzysztof Szade from Jagellonian University in Krakow, Poland, discusses HSPc in health, aging and malignancy. This podcast recaps the findings that aim to elucidate the metabolic requirements of HSCs at different stages of aging. Listen to Dr Szade summarize the data on how heme oxygenase-1 (HO-1) influences glycolytic metabolic stemness of HSCs, impacting on their self-renewal and differentiation. Fo...
Feb 07, 2025•8 min•Ep 132•Transcript available on Metacast This podcast episode highlights the need to use innovative clinical trial designs in the era of increasingly personalized medicine in hematology. Listen to Dr Jurjen Versluis from Erasmus Medical Center in Rotterdam, the Netherlands, discuss his research on this topic. As the amount of novel targeted drugs is increasing, and treatments lead to increasingly better survival outcomes, we need to think about new, adaptive designs that will result in impactful trials in shorter time. Follow Dr Verslu...
Jan 31, 2025•18 min•Ep 131•Transcript available on Metacast As knowledge about hereditary hematological malignancies (HHMs) increases, so do the options for better management of these diseases. Please join us in this podcast to hear Dr Kiran Tawana from Addenbrooke’s Hospital in Cambridge, UK, share her insights on this topic. HHMs are syndromes where two or more cases of cytopenia and hematological malignancy (typically MDS/AML) occur within the same family. Dr Tawana discusses the discovery of HHMs and provides advice on how to recognize them in clinic...
Jan 24, 2025•23 min•Ep 130•Transcript available on Metacast In this podcast, Prof Thorsten Zenz from University Hospital in Zurich, Switzerland, discusses the current approaches to treatment of relapsed hairy cell leukemia (HCL). Based on his personal journey as a hematologist interested in precision oncology, prof. Zenz summarizes the years of accumulating data and clinical experience to explain the treatment approach he often uses for his patients. Thanks to the clear molecular target (V600E mutation of BRAF), treatment of classical hairy cell leukemia...
Jan 20, 2025•18 min•Ep 129•Transcript available on Metacast In this episode of EHA Unplugged, Prof Kirsten Grønbæk and our guests Prof Yelena Ginzburg and Prof Amit Verma discuss iron metabolism and its role in erythropoiesis in MDS. The experts share their views on the management of iron overload in the transfusion-dependent patients with MDS, as they acknowledge that it poses a real challenge in their clinical practice. Starting from the criteria used to select patients for iron chelation and then discussing its beneficial effects and limitations, the ...
Jan 10, 2025•33 min•Ep 128•Transcript available on Metacast In this podcast, Dr Elisabeth Schorb from University Medical Center in Freiburg, Germany, discusses the first-line treatment of primary central nervous system lymphoma (PCNSL), which has seen tremendous advances in the last years. PCNSL is a rare condition, and because of its location prompt diagnosis and timely treatment are of the essence. As for other hematological diseases, treatment of PCNSL today is based on two pillars: induction treatment and consolidation treatment. Listen to Dr Schrob ...
Dec 27, 2024•18 min•Ep 127•Transcript available on Metacast With the increasing scrutiny of healthcare pathways for women, this podcast provides a timely plea by Dr Michelle Lavin from St. James’s Hospital in Dublin, Ireland, to optimize global care for women with von Willebrand disease (VWD). In this podcast, Dr Lavin gives a passionate appeal for more international collaboration and increased awareness to improve care for women and girls suffering from bleeding disorders. As challenges facing women with these disorders are multiple, including diagnosti...
Dec 21, 2024•22 min•Ep 126•Transcript available on Metacast In this lecture from EHA2024, Prof Domenico Girelli from University of Verona, Italy, discusses the complex relationship between iron metabolism and infection. As an essential element for physiology of all living organisms, iron is involved in many vital processes, including our immune responses to infections. Since the pathogens themselves also depend on iron to survive, the resulting host/pathogen “battle” for iron is one of the key determinants of outcomes of most infectious diseases. Interes...
Dec 13, 2024•18 min•Ep 125•Transcript available on Metacast Join us for an insightful lecture by Prof Maria Teresa Voso from University of Rome Tor Vergata in Italy, as she discusses the advances in the treatment of a rare subtype of AML, the acute promyelocytic leukemia (APL). As the PML::RARA rearrangement, resulting in a fusion protein that disrupts retinoic acid signaling and PML function, is the hallmark driver of APL, it is used as target for APL treatment. Listen to Prof Voso as she talks about the scientific developments leading to significant im...
Dec 06, 2024•19 min•Ep 124•Transcript available on Metacast Join us for this engaging debate on the future of acquired TTP (aTTP) treatment chaired by Dr. Eleni Gavriilaki from Aristotle University of Thessaloniki in Greece. This discussion features Prof. Marie Scully from University College London Hospital in UK and Prof. Paul Coppo from Saint-Antoine Hospital in Paris, France. The debate centers on whether therapeutic plasma exchange (PEX) combined with immunosuppression, long considered the standard treatment for acute aTTP episodes, has become obsole...
Nov 29, 2024•17 min•Ep 123•Transcript available on Metacast Join us in this podcast episode to get a glimpse of what the future holds in the big field of innovation in hematology. With the help of our host, Dr Gregor Hormann (MLL Munich Leukemia Laboratory, Germany), you will be taken on a journey toward a future that is already here. Dr Hormann will discuss the many potentials of AI in hematology and oncology, including the automated integrated diagnostic tools, from morphology to chromosomal banding analysis in a few minutes, new clas...
Nov 22, 2024•16 min•Ep 122•Transcript available on Metacast Tune in to EHA Unplugged for an engaging chat with Professor Lars Bullinger from Charité University Medicine, Berlin. He'll break down the latest in myeloid disease classification, discussing how new genetic insights are transforming our understanding of MDS and AML. Discover the hurdles clinicians face, the promise of innovative treatments, and the future of preventive medicine, including the impact of clonal hematopoiesis and cutting-edge sequencing tech. Host: Prof Kirsten Grønbæk...
Nov 18, 2024•21 min•Ep 121•Transcript available on Metacast Join us for an insightful episode featuring Prof David Rees from King’s College Hospital in London as he discusses screening practices for Sickle Cell disease (SCD). Hosted by Dr Sarah de Vlieger, this discussion explores both antenatal and neonatal screening practices for Sickle Cell disease. The conversation begins with an examination of antenatal screening challenges, comparing various techniques such as carrier screening, amniocentesis, chorionic villus sampling, and emerging non-invasive pr...
Nov 08, 2024•18 min•Ep 120•Transcript available on Metacast Join us for an engaging episode with Dr. Stephen Hibbs from Queen Mary University of London as he discusses the environmental impacts of hematology. Alongside our host Dr. Sarah de Vlieger, they explore how climate change is already affecting hematology, emphasizing that these effects are being felt now rather than in the future. The conversation highlights how climate change alters aspects of hematology practice, such as the risk of transfusion-transmitted infections due to evolving disease vec...
Nov 01, 2024•13 min•Ep 119•Transcript available on Metacast Join us in this podcast episode, exploring with Prof Matteo Della Porta (Humanitas Research Hospital, Milano, Italy) the emerging role of "synthetic patients" in hematological clinical trials. Innovative generative artificial intelligence models allow today to create synthetic data set based on real patients, suitable to be used as control groups in clinical trials, helping in the identification of disease mechanisms and improving the prognostic risk prediction. Prof Della Porta will dig into th...
Oct 25, 2024•15 min•Ep 118•Transcript available on Metacast Join us for an insightful interview with Prof Bruno Paiva from Clinical University of Navarra in Pamplona, Spain, as he and our host Dr. Isabel Olivera-Martinez, discuss the latest technical approaches to improving monitoring, risk stratification and differential diagnosis of patients with monoclonal gammopathies including MGUS (monoclonal gammopathy of unknown significance), smoldering myeloma and multiple myeloma. Prof Paiva begins by highlighting the importance of developing less ...
Oct 18, 2024•18 min•Ep 117•Transcript available on Metacast Join us for an interview with Prof Ivo Touw, who has received the prestigious EHA David Grimwade Award for his contributions to the field of hematology research. Prof Touw and his research group focus on molecular signaling in leukemia predisposition syndromes, such as severe congenital neutropenia (SCN). They have described the dysfunction of the membrane receptor for the growth factor G-CSF and its role in SCN and malignant transformation to acute myeloid leukemia. In this interview prof. Touw...
Oct 11, 2024•28 min•Ep 116•Transcript available on Metacast Join us for an insightful interview with Professor Saskia Middeldorp from Radboud University Medical Center in Nijmegen, The Netherlands, as she and our host Dr. Isabel Olivera-Martinez, discuss the medical and ethical challenges of conducting randomized clinical trials to prevent venous thromboembolism (VTE) during pregnancy. VTE is a leading cause of maternal morbidity and mortality, and poses significant risks to pregnant women. Together, explore the relevance of prophylactic treatments...
Oct 04, 2024•16 min•Ep 115•Transcript available on Metacast Join us for an insightful interview with Professor Frank Leebeek from Erasmus University in Rotterdam, The Netherlands, as he discusses together with our host, Dr. Isabel Olivera-Martinez, the potential of gene therapy to free hemophilia patients from the standard coagulation factor replacement therapy. Prof. Leebeek explains how gene therapy for hemophilia is carried out and differentiates the current possibilities for hemophilia A patients versus those with hemophilia B. He also highlights the...
Sep 17, 2024•25 min•Ep 114•Transcript available on Metacast In this podcast episode, we will explore the application of artificial intelligence to morphological diagnosis in hematology. Listening to our host, Dr Mahesh Prahladan (University of Suffolk, UK) you will learn how innovative machine learning and deep learning models have led to the development of AI systems that have been applied in various areas of hematology, including digital pathology. As these systems have shown promise in improving diagnostic accuracy and efficiency, they als...
Sep 06, 2024•13 min•Ep 113•Transcript available on Metacast Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain), the first academic centre to achieve the authorisation to treat patients with a CAR T therapy developed 100% by academia. Prof Delgado discusses the complexities of obtaining regulatory approval for CAR T-cell therapy, under the EU regulation for advanced therapy medicinal products (ATMPs). In this episode, Prof Delgado shares his own experience learning to navigate the EU regulatory ...
Aug 30, 2024•11 min•Ep 112•Transcript available on Metacast Join us for this podcast discussing the promises and challenges of academic and point-of-care CAR T-cell manufacturing with Dr Anna Sureda, president of EBMT ( European Society for Blood and Marrow Transplantation ). Dr Sureda provides her expert point of view on how CAR T-cells produced in academic centres may enhance patient access to CAR-T treatment, reducing costs and turnround times for production, and on the regulatory and quality issues linked to decentralized manufacturing of CAR T...
Aug 23, 2024•22 min•Ep 111•Transcript available on Metacast Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain) as he explains the intricate process of CAR T-cell therapy. In this episode, we cover the key steps involved in CAR T, such as patient identification, apheresis, manufacturing, cell infusion and managing post-infusion related toxicities. Prof Delgado offers expert insights on each component of this complex treatment and discusses possible improvements. He also highlights efforts to shorten vein-to...
Aug 16, 2024•28 min•Ep 110•Transcript available on Metacast Tune in to our podcast for an in-depth discussion on CAR T-cell therapy for acute lymphocytic leukemia (ALL) in children. In this episode, we feature Professor Concetta Quintarelli, a renowned expert in hematology from the Bambino Gesù Children Hospital in Rome. With host Isabel Olivera, they explore the advancements and challenges in treating ALL with CAR T-cells, the balance between treatment efficacy and safety, and the potential of combining CAR T-cells with other immunotherap...
Aug 09, 2024•19 min•Ep 109•Transcript available on Metacast Tune in to our podcast for an in-depth discussion on immunotherapeutic strategies for Acute Myeloid Leukemia (AML). In this episode, we feature Dr Sarah Tettamanti, a senior scientist at the Fondazione Tettamanti Research Centre in Italy, who shares her expertise on CAR T-cell therapy for AML. With host Dr Sarah de Vlieger, they examine the progress and challenges in treating AML with CAR T-cells, the balance between treatment efficacy and safety, and the potential of combining CAR T-cell...
Aug 02, 2024•15 min•Ep 108•Transcript available on Metacast Welcome to a thought-provoking episode of our podcast series, where we dive into the ethical and practical challenges of CAR T-cell therapy with Professor Marie José Kersten from Amsterdam University Medical Centers. In this episode, our host Dr Isabel Olivera engages in a deep dive with Professor Kersten on the intricacies of patient access to CAR T-cell therapy, the ethical considerations in patient selection, and the financial implications of this groundbreaking treatment. Discover the rigoro...
Jul 26, 2024•22 min•Ep 107•Transcript available on Metacast Join us for a conversation with Jonathan Clark, a patient advocate who has been in remission for over five years after receiving CAR T-cell therapy for Mantle Cell Lymphoma. Jonathan shares his journey from relapse to recovery, detailing the challenges and triumphs of this cutting-edge treatment from a patient’s perspective. With host Dr. Sarah de Vlieger, they discuss his motivation for sharing his story and the profound physical and psychological impacts of long-term remission. Jonathan also t...
Jul 19, 2024•12 min•Ep 106•Transcript available on Metacast Join us for a captivating interview with our guest Professor Michael Hudecek from the Universitätsklinikum Würzburg in Germany as he offers his insights on the latest advancements in CAR T-cell therapy and gene-engineered immune cell therapies. Together with our host Dr. Isabel Olivera Martinez, they discuss the mounting real-world data on CAR T-cell treatments and how AI is helping analyze this data to design new strategies and extend CAR-T to new indications. Discover the strides being m...
Jul 12, 2024•18 min•Ep 105•Transcript available on Metacast 
